Cargando…
Evaluation of the Clinical Systems for Polymyxin Susceptibility Testing of Clinical Gram-Negative Bacteria in China
OBJECTIVES: The performance of mainstream commercial antimicrobial susceptibility testing systems on polymyxins has not been well evaluated in China. In this study, three antimicrobial susceptibility testing systems were evaluated for polymyxin B and colistin. METHODS: The MICs of 257 Gram-negative...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7937900/ https://www.ncbi.nlm.nih.gov/pubmed/33692761 http://dx.doi.org/10.3389/fmicb.2020.610604 |
_version_ | 1783661488392634368 |
---|---|
author | Zhu, Ying Jia, Peiyao Zhou, Menglan Zhang, Jingjia Zhang, Ge Kang, Wei Duan, Simeng Wang, Tong Xu, Yingchun Yang, Qiwen |
author_facet | Zhu, Ying Jia, Peiyao Zhou, Menglan Zhang, Jingjia Zhang, Ge Kang, Wei Duan, Simeng Wang, Tong Xu, Yingchun Yang, Qiwen |
author_sort | Zhu, Ying |
collection | PubMed |
description | OBJECTIVES: The performance of mainstream commercial antimicrobial susceptibility testing systems on polymyxins has not been well evaluated in China. In this study, three antimicrobial susceptibility testing systems were evaluated for polymyxin B and colistin. METHODS: The MICs of 257 Gram-negative strains collected from clinical cases and livestock were determined and analyzed. Using Broth Microdilution as the gold standard, the performance of VITEK 2(®) COMPACT, Phoenix(TM) M50, and Bio-kont AST System were evaluated. Essential agreement (EA), category agreement (CA), very major error (VME), and major error (ME) were calculated for comparison. The results of mcr-1 positive strains were separately discussed. RESULTS: The EA, CA, VME, and ME to polymyxin B for Bio-kont were 83.5, 95.6, 13.1, and 0.6%, respectively. The EAs, CAs, VMEs, and MEs to colistin were as follows: Bio-kont, 86.7%/96.5%/7.2%/1.7%; Vitek 2, 64.2%/86.8%/41.0%/0%, and Phoenix M50, 92.9%/92.9%/21.7%/0%. The performance of Bio-kont to polymyxin B and colistin for Pseudomonas spp. (EA, CA < 90%, VME > 1.5%, ME = 5.6%/10%) and Enterobacter spp. (EA, CA < 90%, VME > 1.5% and ME = 0%), Vitek to colistin for most genera, and Phoenix to colistin for Enterobacter spp. (EA, CA < 90%, VME > 1.5%, ME = 0%) were unsatisfactory compared with other genera. The performance of Bio-kont to polymyxins for Escherichia spp. and Phoenix to colistin for Citrobacter spp., Escherichia spp., and Klebsiella spp., which all met the CLSI standard, were satisfactory. When the susceptibility of mcr-1 positive E. coli was tested, Bio-kont and Phoenix M50 presented excellent performance with no category errors, while Vitek 2 performed a high VME (25.5%). CONCLUSION: With relatively more accurate results for polymyxin B and colistin and lower VME, Bio-kont has an advantage in polymyxin antimicrobial susceptibility testing, especially for Escherichia spp., Klebsiella spp., Citrobacter spp. and Acinetobacter spp. |
format | Online Article Text |
id | pubmed-7937900 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79379002021-03-09 Evaluation of the Clinical Systems for Polymyxin Susceptibility Testing of Clinical Gram-Negative Bacteria in China Zhu, Ying Jia, Peiyao Zhou, Menglan Zhang, Jingjia Zhang, Ge Kang, Wei Duan, Simeng Wang, Tong Xu, Yingchun Yang, Qiwen Front Microbiol Microbiology OBJECTIVES: The performance of mainstream commercial antimicrobial susceptibility testing systems on polymyxins has not been well evaluated in China. In this study, three antimicrobial susceptibility testing systems were evaluated for polymyxin B and colistin. METHODS: The MICs of 257 Gram-negative strains collected from clinical cases and livestock were determined and analyzed. Using Broth Microdilution as the gold standard, the performance of VITEK 2(®) COMPACT, Phoenix(TM) M50, and Bio-kont AST System were evaluated. Essential agreement (EA), category agreement (CA), very major error (VME), and major error (ME) were calculated for comparison. The results of mcr-1 positive strains were separately discussed. RESULTS: The EA, CA, VME, and ME to polymyxin B for Bio-kont were 83.5, 95.6, 13.1, and 0.6%, respectively. The EAs, CAs, VMEs, and MEs to colistin were as follows: Bio-kont, 86.7%/96.5%/7.2%/1.7%; Vitek 2, 64.2%/86.8%/41.0%/0%, and Phoenix M50, 92.9%/92.9%/21.7%/0%. The performance of Bio-kont to polymyxin B and colistin for Pseudomonas spp. (EA, CA < 90%, VME > 1.5%, ME = 5.6%/10%) and Enterobacter spp. (EA, CA < 90%, VME > 1.5% and ME = 0%), Vitek to colistin for most genera, and Phoenix to colistin for Enterobacter spp. (EA, CA < 90%, VME > 1.5%, ME = 0%) were unsatisfactory compared with other genera. The performance of Bio-kont to polymyxins for Escherichia spp. and Phoenix to colistin for Citrobacter spp., Escherichia spp., and Klebsiella spp., which all met the CLSI standard, were satisfactory. When the susceptibility of mcr-1 positive E. coli was tested, Bio-kont and Phoenix M50 presented excellent performance with no category errors, while Vitek 2 performed a high VME (25.5%). CONCLUSION: With relatively more accurate results for polymyxin B and colistin and lower VME, Bio-kont has an advantage in polymyxin antimicrobial susceptibility testing, especially for Escherichia spp., Klebsiella spp., Citrobacter spp. and Acinetobacter spp. Frontiers Media S.A. 2021-02-22 /pmc/articles/PMC7937900/ /pubmed/33692761 http://dx.doi.org/10.3389/fmicb.2020.610604 Text en Copyright © 2021 Zhu, Jia, Zhou, Zhang, Zhang, Kang, Duan, Wang, Xu and Yang. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Microbiology Zhu, Ying Jia, Peiyao Zhou, Menglan Zhang, Jingjia Zhang, Ge Kang, Wei Duan, Simeng Wang, Tong Xu, Yingchun Yang, Qiwen Evaluation of the Clinical Systems for Polymyxin Susceptibility Testing of Clinical Gram-Negative Bacteria in China |
title | Evaluation of the Clinical Systems for Polymyxin Susceptibility Testing of Clinical Gram-Negative Bacteria in China |
title_full | Evaluation of the Clinical Systems for Polymyxin Susceptibility Testing of Clinical Gram-Negative Bacteria in China |
title_fullStr | Evaluation of the Clinical Systems for Polymyxin Susceptibility Testing of Clinical Gram-Negative Bacteria in China |
title_full_unstemmed | Evaluation of the Clinical Systems for Polymyxin Susceptibility Testing of Clinical Gram-Negative Bacteria in China |
title_short | Evaluation of the Clinical Systems for Polymyxin Susceptibility Testing of Clinical Gram-Negative Bacteria in China |
title_sort | evaluation of the clinical systems for polymyxin susceptibility testing of clinical gram-negative bacteria in china |
topic | Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7937900/ https://www.ncbi.nlm.nih.gov/pubmed/33692761 http://dx.doi.org/10.3389/fmicb.2020.610604 |
work_keys_str_mv | AT zhuying evaluationoftheclinicalsystemsforpolymyxinsusceptibilitytestingofclinicalgramnegativebacteriainchina AT jiapeiyao evaluationoftheclinicalsystemsforpolymyxinsusceptibilitytestingofclinicalgramnegativebacteriainchina AT zhoumenglan evaluationoftheclinicalsystemsforpolymyxinsusceptibilitytestingofclinicalgramnegativebacteriainchina AT zhangjingjia evaluationoftheclinicalsystemsforpolymyxinsusceptibilitytestingofclinicalgramnegativebacteriainchina AT zhangge evaluationoftheclinicalsystemsforpolymyxinsusceptibilitytestingofclinicalgramnegativebacteriainchina AT kangwei evaluationoftheclinicalsystemsforpolymyxinsusceptibilitytestingofclinicalgramnegativebacteriainchina AT duansimeng evaluationoftheclinicalsystemsforpolymyxinsusceptibilitytestingofclinicalgramnegativebacteriainchina AT wangtong evaluationoftheclinicalsystemsforpolymyxinsusceptibilitytestingofclinicalgramnegativebacteriainchina AT xuyingchun evaluationoftheclinicalsystemsforpolymyxinsusceptibilitytestingofclinicalgramnegativebacteriainchina AT yangqiwen evaluationoftheclinicalsystemsforpolymyxinsusceptibilitytestingofclinicalgramnegativebacteriainchina |